TITLE

The expression and functional role of FOX transcription factor FOXJ1 in prostate cancer

AUTHOR(S)
Qi An; Dezhong Liu; Lian Zou
PUB. DATE
January 2017
SOURCE
International Journal of Clinical & Experimental Medicine;2017, Vol. 10 Issue 1, p285
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
As one common malignant tumor in male reproductive-urinary system, the incidence of prostate cancer is increasing rapidly. Recent study revealed the participation of FOX transcription factor family in tumor occurrence and progression. FOXJ1, one member of FOX family, plays an important role in tumor pathogenesis and advancement, although its expression and functional role in prostate cancer has not been illustrated. Both tumor and adjacent tissues were collected from prostate cancer patients. Real-time PCR and Western blot were used to test the FOXJ1 expressions, and to analyze their correlation with pathological feature of cancer. DU145 cells were in vitro cultured and were transfected with FOXJ1-overexpressing vectors. MTT assay detected the effect of FOXJ1 on tumor cell proliferation. Western blot quantified MMP-2 and MMP-9 expressions, while Transwell invasion assay determined the impact of FOXJ1 on tumor invasion. Both mRNA and protein levels of FOXJ1 in prostate tumor tissues were significantly depressed compared to adjacent tissues (P<0.05). FOXJ1 expression level was negatively correlated with TNM stage, tumor volume and lymphatic metastasis (P<0.05). The transfection of DU145 cells by FOXJ1-overexpressed vectors inhibited proliferation or invasion abilities, and reduced MMP-2 and MMP-9 expressions (P<0.05 compared to control group). FOXJ1 was down-regulated in prostate cancer tissues, and was closely correlated with pathological features of tumor. FOXJ1 regulated proliferation of prostate cancer cells, and functioned as molecular targets for tumor diagnosis and prognostic prediction via modulating MMP-2 and MMP-9 mediated tumor invasion.
ACCESSION #
120898340

 

Related Articles

  • β-Arrestin2 Contributes to Cell Viability and Proliferation via the Down-Regulation of FOXO1 in Castration-Resistant Prostate Cancer. Duan, Xiaolu; Kong, Zhenzhen; Liu, Yang; Zeng, Zhiwen; Li, Shujue; Wu, Wenqi; Ji, Weidong; Yang, Bicheng; Zhao, Zhijian; Zeng, Guohua // Journal of Cellular Physiology;Oct2015, Vol. 230 Issue 10, p2371 

    β-Arrestin2 has been identified to act as a corepressor of androgen receptor (AR) signaling by binding to AR and serving as a scaffold to affect the activity and expression of AR in androgen-dependent prostate cancer cells; however, little is known regarding its role in castration-resistant...

  • Role of Androgen Receptor in Progression of LNCaP Prostate Cancer Cells from G1 to S Phase. Murthy, Shalini; Wu, Min; Bai, V. Uma; Hou, Zizheng; Menon, Mani; Barrack, Evelyn R.; Kim, Sahn-Ho; Reddy, G. Prem-Veer // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Background: The androgen receptor (AR) plays a critical role in the proliferation of prostate cancer cells. However, its mechanism of action in proliferation remains unknown. An understanding of the mechanism of AR action in proliferation may lead to the development of effective strategies for...

  • GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer. Naiki, Taku; Naiki-Ito, Aya; Asamoto, Makoto; Kawai, Noriyasu; Tozawa, Keiichi; Etani, Toshiki; Sato, Shinya; Suzuki, Shugo; Shirai, Tomoyuki; Kohri, Kenjiro; Takahashi, Satoru // Carcinogenesis;Sep2014, Vol. 35 Issue 9, p1962 

    GPX2 overexpression in CRPC increased cell growth through ROS regulation in a cell cycle-dependent manner. Moreover, patients with highly expressed GPX2 had significantly poorer prognosis. These findings suggest that GPX2 may be a prognostic marker and therapeutic target for CRPC.There is a need...

  • Inhibition on Proteasome β1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells. Li, Dong; Lu, Yu; Sun, Peng; Feng, Li-Xing; Liu, Miao; Hu, Li-Hong; Wu, Wan-Ying; Jiang, Bao-Hong; Yang, Min; Qu, Xiao-Bo; Guo, De-An; Liu, Xuan // PLoS ONE;29/10/2015, Vol. 10 Issue 10, p1 

    Fangchinoline is a bisbenzylisoquinoline alkaloid isolated from Radix Stephaniae tetrandrae S. Moore. Fangchinoline and its structure analogue, tetrandrine, exhibited direct binding affinity with recombinant human proteasome β1 subunit and also inhibited its activity in vitro. In cultured...

  • Go forth and multiply. Robey, Rebecca // Nature Reviews Cancer;Jan2007, Vol. 7 Issue 1, p8 

    The article discusses the research by Colin Goding and colleagues on proliferation or metastasis of melanoma cells due to the microphthalmia-associated transcription factor (MITF). The ability of the melanoma cells to form tumors is hindered by the ectopic expression of MITF. The research...

  • Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Melling, Nathaniel; Thomsen, Erik; Tsourlakis, Maria Christina; Kluth, Martina; Hube-Magg, Claudia; Minner, Sarah; Koop, Christina; Graefen, Markus; Heinzer, Hans; Wittmer, Corinna; Sauter, Guido; Wilczak, Waldemar; Huland, Hartwig; Simon, Ronald; Schlomm, Thorsten; Steurer, Stefan; Krech, Till // Carcinogenesis;Nov2015, Vol. 36 Issue 11, p1333 

    Enhancer of zeste homolog 2 (EZH2) plays an important role in tumor development and progression by interacting with histone and nonhistone proteins. In the current study, we analyzed prevalence and prognostic impact of EZH2 in prostate cancer. EZH2 expression was analyzed by immunohistochemistry...

  • Predictive Clinical Indicators of Biochemical Progression in Advanced Prostate Cancer Patients Receiving Leuplin Depot as Androgen Deprivation Therapy. Chen, Chien-Hua; Hsieh, Ju-Ton; Huang, Kuo-How; Pu, Yeong-Shiau; Chang, Hong-Chiang // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Therapeutic planning and counseling for advanced prostate cancer patients receiving androgen deprivation therapy (ADT) is complicated because the prognoses are highly variable. The purpose of this study is to identify predictive clinical indicators of biochemical progression (BCP). In this...

  • VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy. Tsourlakis, Maria Christina; Khosrawi, Puya; Weigand, Philipp; Kluth, Martina; Hube-Magg, Claudia; Minner, Sarah; Koop, Christina; Graefen, Markus; Heinzer, Hans; Wittmer, Corinna; Sauter, Guido; Krech, Till; Wilczak, Waldemar Wilczak; Huland, Hartwig; Simon, Ronald; Schlomm, Thorsten; Steurer, Stefan // International Journal of Molecular Sciences;2015, Vol. 16 Issue 4, p8591 

    The VEGFR-1 is suggested to promote tumor progression. In the current study we analyzed prevalence and prognostic impact of the VEGFR-1 by immunohistochemistry on a tissue microarray containing more than 3000 prostate cancer specimens. Results were compared to tumor phenotype, ETS-related gene...

  • Risk stratification of prostate cancer patients based on EPS-urine zinc content. Medarova, Zdravka; Ghosh, Subrata K.; Vangel, Mark; Drake, Richard; Moore, Anna // American Journal of Cancer Research;2014, Vol. 4 Issue 4, p385 

    The early detection of prostate cancer is a life-saving event in patients harboring potentially aggressive disease. With the development of malignancy there is a dramatic reduction in the zinc content of prostate tissue associated with the inability of cancer cells to accumulate the ion. In the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics